JP2015516373A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015516373A5 JP2015516373A5 JP2014561519A JP2014561519A JP2015516373A5 JP 2015516373 A5 JP2015516373 A5 JP 2015516373A5 JP 2014561519 A JP2014561519 A JP 2014561519A JP 2014561519 A JP2014561519 A JP 2014561519A JP 2015516373 A5 JP2015516373 A5 JP 2015516373A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic
- prophylactic agent
- particles
- agent according
- carbon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 137
- 229910052799 carbon Inorganic materials 0.000 claims description 136
- 239000011148 porous material Substances 0.000 claims description 34
- 239000002245 particle Substances 0.000 claims description 31
- 239000003795 chemical substances by application Substances 0.000 claims description 27
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 19
- 206010016654 Fibrosis Diseases 0.000 claims description 10
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 9
- 208000008589 Obesity Diseases 0.000 claims description 7
- 235000020824 obesity Nutrition 0.000 claims description 7
- 230000007882 cirrhosis Effects 0.000 claims description 6
- 230000003870 intestinal permeability Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 4
- 230000004761 fibrosis Effects 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 238000001179 sorption measurement Methods 0.000 claims description 4
- 208000007386 hepatic encephalopathy Diseases 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims 24
- 230000000069 prophylactic effect Effects 0.000 claims 23
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 239000004480 active ingredient Substances 0.000 claims 6
- 208000019423 liver disease Diseases 0.000 claims 6
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 5
- 230000000968 intestinal effect Effects 0.000 claims 5
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 201000003146 cystitis Diseases 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 206010003445 Ascites Diseases 0.000 claims 1
- 208000010334 End Stage Liver Disease Diseases 0.000 claims 1
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 230000009798 acute exacerbation Effects 0.000 claims 1
- 208000011444 chronic liver failure Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000029182 enterotoxemia Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 208000007232 portal hypertension Diseases 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000012798 spherical particle Substances 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 201000001862 viral hepatitis Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 33
- 239000002158 endotoxin Substances 0.000 description 24
- 230000037213 diet Effects 0.000 description 21
- 235000005911 diet Nutrition 0.000 description 21
- 229920006008 lipopolysaccharide Polymers 0.000 description 21
- 210000000013 bile duct Anatomy 0.000 description 15
- 210000001865 kupffer cell Anatomy 0.000 description 13
- 230000007423 decrease Effects 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 206010067125 Liver injury Diseases 0.000 description 9
- 231100000234 hepatic damage Toxicity 0.000 description 9
- 230000008818 liver damage Effects 0.000 description 9
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 8
- 230000002950 deficient Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 6
- 108010082126 Alanine transaminase Proteins 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 229960001231 choline Drugs 0.000 description 6
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 210000003608 fece Anatomy 0.000 description 5
- 238000013116 obese mouse model Methods 0.000 description 5
- 241000606125 Bacteroides Species 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 4
- 229910052753 mercury Inorganic materials 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000002459 porosimetry Methods 0.000 description 3
- 210000003240 portal vein Anatomy 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000002485 combustion reaction Methods 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000011013 endotoxin removal Methods 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100025222 CD63 antigen Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
Images
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1204696.7A GB201204696D0 (en) | 2012-03-16 | 2012-03-16 | Therapy |
| GB1204696.7 | 2012-03-16 | ||
| PCT/GB2013/050673 WO2013136094A1 (en) | 2012-03-16 | 2013-03-15 | Porous carbon particles for use in the treatment or prevention of liver disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018023609A Division JP6647570B2 (ja) | 2012-03-16 | 2018-02-14 | 肝疾患の治療及び予防における使用のための多孔性炭素粒子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015516373A JP2015516373A (ja) | 2015-06-11 |
| JP2015516373A5 true JP2015516373A5 (enExample) | 2016-05-12 |
| JP6293680B2 JP6293680B2 (ja) | 2018-03-14 |
Family
ID=46052080
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014561519A Active JP6293680B2 (ja) | 2012-03-16 | 2013-03-15 | 肝疾患の治療及び予防における使用のための多孔性炭素粒子 |
| JP2018023609A Active JP6647570B2 (ja) | 2012-03-16 | 2018-02-14 | 肝疾患の治療及び予防における使用のための多孔性炭素粒子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018023609A Active JP6647570B2 (ja) | 2012-03-16 | 2018-02-14 | 肝疾患の治療及び予防における使用のための多孔性炭素粒子 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9844568B2 (enExample) |
| EP (2) | EP2825181B1 (enExample) |
| JP (2) | JP6293680B2 (enExample) |
| KR (2) | KR102441934B1 (enExample) |
| CN (1) | CN104363916B (enExample) |
| AU (1) | AU2013234099B2 (enExample) |
| BR (1) | BR112014022810B1 (enExample) |
| DK (1) | DK2825181T3 (enExample) |
| EA (1) | EA038965B1 (enExample) |
| GB (1) | GB201204696D0 (enExample) |
| IN (1) | IN2014DN07637A (enExample) |
| MY (1) | MY169093A (enExample) |
| NZ (1) | NZ631429A (enExample) |
| SG (1) | SG11201405771QA (enExample) |
| WO (1) | WO2013136094A1 (enExample) |
| ZA (1) | ZA201406989B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201204696D0 (en) * | 2012-03-16 | 2012-05-02 | Ucl Business Plc | Therapy |
| ES2727153T3 (es) * | 2014-04-17 | 2019-10-14 | Immutrix Therapeutics Inc | Composiciones de destoxificación terapéutica y métodos para la preparación y utilización de las mismas |
| TWI607765B (zh) * | 2014-08-27 | 2017-12-11 | Kureha Corp | Adsorbents for oral administration, and nephropathy therapeutic agents and liver disease therapeutic agents |
| KR102328323B1 (ko) | 2017-03-31 | 2021-11-19 | 엑시얼 테라퓨틱스, 인크. | 자폐증 및 관련 장애의 치료 및 예방을 위한 장-선택적 봉쇄제 |
| EP3476818A1 (en) | 2017-10-27 | 2019-05-01 | Heraeus Battery Technology GmbH | A process for the preparation of a porous carbon material using an improved carbon source |
| EP3476817A1 (en) | 2017-10-27 | 2019-05-01 | Heraeus Battery Technology GmbH | A process for the preparation of a porous carbon material using an improved amphiphilic species |
| WO2019131209A1 (ja) * | 2017-12-27 | 2019-07-04 | 株式会社クラレ | 活性炭およびその製法 |
| JP7228498B2 (ja) * | 2018-10-24 | 2023-02-24 | フタムラ化学株式会社 | フェノール樹脂の製造方法 |
| WO2020085282A1 (ja) * | 2018-10-24 | 2020-04-30 | フタムラ化学株式会社 | フェノール樹脂の製造方法 |
| JP7338993B2 (ja) * | 2019-03-06 | 2023-09-05 | 株式会社クラレ | 多孔質炭素および多孔質炭素の製造方法 |
| JP7061640B2 (ja) * | 2019-04-16 | 2022-04-28 | フタムラ化学株式会社 | 活性炭吸着剤の製造方法 |
| WO2020213559A1 (ja) * | 2019-04-16 | 2020-10-22 | フタムラ化学株式会社 | 活性炭吸着剤の製造方法 |
| JP7563145B2 (ja) * | 2019-12-05 | 2024-10-08 | ａｒｔｉｅｎｃｅ株式会社 | 多孔質炭素及びその製造方法 |
| WO2024261472A1 (en) * | 2023-06-20 | 2024-12-26 | Yaqrit Limited | Porous carbon particles for use in therapy |
| KR102971111B1 (ko) | 2023-09-05 | 2026-06-02 | 한국생산기술연구원 | 열경화성 에폭시 조성물, 이의 경화물 및 용도 |
| CN121925310A (zh) * | 2025-03-28 | 2026-04-24 | 大阪燃气化学有限公司 | 麻醉气体吸附剂、麻醉气体吸附过滤器、吸入麻醉系统以及麻醉气体的去除方法 |
| JP7724390B1 (ja) * | 2025-03-28 | 2025-08-15 | 大阪ガスケミカル株式会社 | 麻酔ガス吸着剤、麻酔ガス吸着剤の製造方法、麻酔ガス吸着フィルター、吸入麻酔システム、および、麻酔ガスの除去方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5332637B2 (enExample) * | 1973-05-09 | 1978-09-09 | ||
| JPS51151693A (en) | 1975-06-23 | 1976-12-27 | Eisai Co Ltd | Coated bead-like activated carbon for blood purification |
| JPS5673542A (en) | 1979-11-22 | 1981-06-18 | Kureha Chem Ind Co Ltd | Adsorbent |
| JPS5731864A (en) * | 1980-08-04 | 1982-02-20 | Teijin Ltd | Oral activated carbon microcapsule |
| RU2177319C2 (ru) * | 1999-03-30 | 2001-12-27 | Российская медицинская академия последипломного образования МЗ РФ | Способ лечения гиперэндотоксинемии |
| GB0019417D0 (en) | 2000-08-09 | 2000-09-27 | Mat & Separations Tech Int Ltd | Mesoporous carbons |
| JP3522708B2 (ja) | 2001-04-11 | 2004-04-26 | 呉羽化学工業株式会社 | 経口投与用吸着剤 |
| JP4311923B2 (ja) * | 2002-10-07 | 2009-08-12 | 株式会社クレハ | 経口投与用肝疾患治療又は予防剤 |
| EP1407772B9 (en) | 2002-10-09 | 2007-02-21 | Kureha Corporation | Pharmaceutical composition comprising porous spherical carbonaceous substance and its use for the treatment of renal and liver diseases |
| CA2504517C (en) | 2002-11-01 | 2008-08-12 | Kureha Corporation | Adsorbent for oral administration, and agent for treating or preventing renal or liver disease |
| US7651974B2 (en) | 2002-11-01 | 2010-01-26 | Kureha Chemical Industry Co., Ltd. | Adsorbent for oral administration |
| JP2005089306A (ja) * | 2003-09-12 | 2005-04-07 | Ajinomoto Co Inc | 炎症性腸疾患治療用の経直腸投与製剤 |
| JP4382629B2 (ja) * | 2003-10-22 | 2009-12-16 | 株式会社クレハ | 経口投与用吸着剤、並びに腎疾患治療又は予防剤、及び肝疾患治療又は予防剤 |
| KR101135260B1 (ko) * | 2003-10-22 | 2012-04-12 | 가부시키가이샤 쿠레하 | 경구투여용 흡착제, 신질환 치료 또는 예방제 및 간질환치료 또는 예방제 |
| TWI370013B (en) * | 2004-04-02 | 2012-08-11 | Kureha Corp | Adsorbent for oral administration, and agent for treating or preventing renal or liver disease |
| TWI370012B (en) | 2004-04-02 | 2012-08-11 | Kureha Corp | Adsorbent for oral administration, and agent for treating or preventing renal or liver disease |
| JP2007045775A (ja) | 2005-08-11 | 2007-02-22 | Japan Organo Co Ltd | 含水活性炭及びその製造方法 |
| DE102005062160A1 (de) | 2005-12-19 | 2007-06-21 | BLüCHER GMBH | Aktivkohle für die medizinische Verwendung |
| US8048413B2 (en) | 2006-05-17 | 2011-11-01 | Helene Huguet | Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules |
| CA2660883C (en) | 2006-10-09 | 2014-12-09 | British American Tobacco (Investments) Limited | Carbonising and/or activating carbonaceous material |
| BRPI0719161A2 (pt) | 2006-10-09 | 2014-02-04 | British American Tobacco Co | Processos para produzir glóbulos sólidos discretos de material polimérico, para preparar um produto de carbono ativado, e para preparar um produto particulado carbonizado, aparelho para formar glóbulos sólidos discretos de material polimérico, métodos para carbonizar e ativar material carbonáceo, e para preparar carbono ativado, e, forno rotativo. |
| WO2010138519A2 (en) | 2009-05-27 | 2010-12-02 | Ocera Therapeutics, Inc. | Use of adsorbent carbon microspheres for the treatment of pruritus |
| GB0921528D0 (en) * | 2009-12-09 | 2010-01-27 | Mast Carbon Internat Ltd | Carbon and its use in blood cleansing applications |
| PL2538930T3 (pl) | 2010-02-23 | 2016-11-30 | Preparaty do doustnego dostarczania środków adsorbujących do jelita | |
| JP5984352B2 (ja) * | 2010-10-12 | 2016-09-06 | フタムラ化学株式会社 | 経口投与用医薬用吸着剤の製造方法 |
| GB201204696D0 (en) * | 2012-03-16 | 2012-05-02 | Ucl Business Plc | Therapy |
-
2012
- 2012-03-16 GB GBGB1204696.7A patent/GB201204696D0/en not_active Ceased
-
2013
- 2013-03-15 JP JP2014561519A patent/JP6293680B2/ja active Active
- 2013-03-15 DK DK13711116.7T patent/DK2825181T3/da active
- 2013-03-15 WO PCT/GB2013/050673 patent/WO2013136094A1/en not_active Ceased
- 2013-03-15 EP EP13711116.7A patent/EP2825181B1/en active Active
- 2013-03-15 BR BR112014022810-8A patent/BR112014022810B1/pt active IP Right Grant
- 2013-03-15 US US14/385,332 patent/US9844568B2/en active Active
- 2013-03-15 KR KR1020207022420A patent/KR102441934B1/ko active Active
- 2013-03-15 CN CN201380025257.6A patent/CN104363916B/zh active Active
- 2013-03-15 SG SG11201405771QA patent/SG11201405771QA/en unknown
- 2013-03-15 NZ NZ631429A patent/NZ631429A/en unknown
- 2013-03-15 IN IN7637DEN2014 patent/IN2014DN07637A/en unknown
- 2013-03-15 AU AU2013234099A patent/AU2013234099B2/en active Active
- 2013-03-15 MY MYPI2014002656A patent/MY169093A/en unknown
- 2013-03-15 EA EA201491690A patent/EA038965B1/ru unknown
- 2013-03-15 KR KR1020147029083A patent/KR102142504B1/ko active Active
- 2013-03-15 EP EP19211615.0A patent/EP3650031B1/en active Active
-
2014
- 2014-09-25 ZA ZA2014/06989A patent/ZA201406989B/en unknown
-
2018
- 2018-02-14 JP JP2018023609A patent/JP6647570B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Arasu et al. | In vitro importance of probiotic Lactobacillus plantarum related to medical field | |
| De Marco et al. | Probiotic cell‐free supernatants exhibited anti‐inflammatory and antioxidant activity on human gut epithelial cells and macrophages stimulated with LPS | |
| Fábrega et al. | Intestinal anti-inflammatory effects of outer membrane vesicles from Escherichia coli Nissle 1917 in DSS-experimental colitis in mice | |
| Yu et al. | D-limonene exhibits anti-inflammatory and antioxidant properties in an ulcerative colitis rat model via regulation of iNOS, COX-2, PGE2 and ERK signaling pathways | |
| Hao et al. | The antidiabetic effects of Bifidobacterium longum subsp. longum BL21 through regulating gut microbiota structure in type 2 diabetic mice | |
| Woo et al. | Lactobacillus pentosus var. plantarum C29 ameliorates memory impairment and inflammaging in a D-galactose-induced accelerated aging mouse model | |
| Tung et al. | Bovine lactoferrin inhibits lung cancer growth through suppression of both inflammation and expression of vascular endothelial growth factor | |
| AU2021206871B2 (en) | Gut-selective sequestering agents for the treatment and prevention of autism and related disorders | |
| ES2686545T3 (es) | Método de tratamiento de la inflamación | |
| Yi et al. | Cathelicidin-BF suppresses intestinal inflammation by inhibiting the nuclear factor-κB signaling pathway and enhancing the phagocytosis of immune cells via STAT-1 in weanling piglets | |
| Jia et al. | Sulfated polysaccharides from pacific abalone attenuated DSS-induced acute and chronic ulcerative colitis in mice via regulating intestinal micro-ecology and the NF-κB pathway | |
| Li et al. | The anti-inflammatory effect and mucosal barrier protection of Clostridium butyricum RH2 in ceftriaxone-induced intestinal dysbacteriosis | |
| Xu et al. | Effective regulation of gut microbiota with probiotics and prebiotics may prevent or alleviate COVID-19 through the gut-lung axis | |
| Kim et al. | Lactobacillus brevis OK56 ameliorates high-fat diet-induced obesity in mice by inhibiting NF-κB activation and gut microbial LPS production | |
| Mansurov et al. | Nanostructured carbon materials for biomedical use | |
| CN116509902B (zh) | 一种通过调节肠-脑轴改善由环境污染引起的精神类疾病的益生菌剂及其应用 | |
| CN104363916A (zh) | 用于治疗或预防肝病的用途的多孔碳颗粒 | |
| Kumar et al. | Immunomodulatory effects of Bifidobacterium bifidum 231 on trinitrobenzenesulfonic acid-induced ulcerative colitis in rats | |
| Morsli et al. | Probiotics in colorectal cancer prevention and therapy: mechanisms, benefits, and challenges | |
| Peng et al. | Early life administration of Bifidobacterium bifidum BD-1 alleviates long-term colitis by remodeling the gut microbiota and promoting intestinal barrier development | |
| Luo et al. | Astaxanthin nanoparticles ameliorate dextran sulfate sodium-induced colitis by alleviating oxidative stress, regulating intestinal flora, and protecting the intestinal barrier | |
| Alliger et al. | Menthacarin attenuates experimental colitis | |
| Kang et al. | Inhibition of trypsin-induced mast cell activation by water fraction of Lonicera japonica | |
| Hung et al. | Evaluation of active carbon fibers used in cell biocompatibility and rat cystitis treatment | |
| Huang et al. | Lactobacillus rhamnosus confers protection against colorectal cancer in rats. |